Search Results
Showing Results for progression-free survival
At ASCO 2025, cervical cancer took centre stage in gynecologic oncology with data showing how immunotherapy is redefining the treatment landscape. Trials such as KEYNOTE-826 and KEYNOTE-A18 demonstrated meaningful gains in survival, while emerging antibody–drug conjugates point to a new wave of personalised therapy for this historically underserved disease.
With #ASCO25 still fresh in our minds, touchONCOLOGY Editorial Board members Dr Fatemeh Ardeshir-Larijani (Emory School of Medicine, Atlanta, GA, USA) and Dr Gabirel Lenz (Hospital Regional Terezinha Gaio Basso, São Miguel Do Oeste, Brazil) reflect on their top key breakthroughs and take-aways from the conference in non-small cell lung cancer (NSCLC).
At #ASCO25, Dr Frank Sinicrope discussed major colon cancer trial updates, including ctDNA’s prognostic power post-surgery, the limitations of chemotherapy escalation in high-risk patients, and survival gains with first-line encorafenib + cetuximab + mFOLFOX6 in BRAF-mutant mCRC. These findings may reshape risk stratification and frontline treatment strategies.
The VERITAC-2 trial is a pivotal, randomized phase III trial evaluating vepdegestrant, a novel oral PROTAC estrogen receptor degrader, in patients with ER-positive, HER2-negative advanced breast cancer. In this interview, Dr Erika Hamilton (Director, Breast Cancer Research, Sarah Cannon ...
#ASCO25: SERENA-6, DESTINY-Breast09, ASCENT-04 – top breast cancer breakthroughs you need to know!
ASCO 2025 showcased transformative breast cancer data. The SERENA-6 trial introduced a novel ctDNA-driven approach for ESR1 mutations, improving PFS with camizestrant. DESTINY-Breast09 supported trastuzumab deruxtecan in first-line HER2-positive disease, while ASCENT-04 showed promise for sacituzumab govitecan plus immunotherapy in triple-negative breast cancer—heralding major shifts in clinical practice.
At #ASCO25, Professor Dickon Hayne presented results from the ANZUP 1301 trial showing that adding mitomycin C to BCG may offer a well-tolerated, effective option for high-risk NMIBC. The combination reduced BCG use by 40% – a significant finding amid global shortages – with encouraging efficacy and safety signals.
Dr. Sara Tolaney discusses ASCENT-04, a phase III trial showing that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival versus chemotherapy plus pembrolizumab in PD-L1–positive metastatic TNBC. With a PFS of 11.2 months and a hazard ratio of 0.65, the combination may represent a new first-line treatment standard.
DESTINY-Breast09 interim results show that trastuzumab deruxtecan plus pertuzumab significantly improves progression-free survival compared to standard THP in first-line treatment for metastatic HER2-positive breast cancer. With a median PFS of 40.7 months versus 26.9 months, the data suggest a potential shift in the treatment paradigm.
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1Â Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2Â Head and neck squamous cell carcinoma (...
Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...
Liquid biopsy: Initial concepts and application in solid tumours The US National Cancer Institute defines liquid biopsy (LB) as ‘a test done on a sample of blood to look for cancer cells from a tumour that are circulating in the ...
Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important ...
touchONCOLOGY presents the top new clinical trial findings that are generating a buzz among prostate cancer experts. Here’s the latest from one of the leading global conferences in GU oncology: the 2025 ASCO Genitourinary Cancers Symposium (February 26–28, 2025, San Francisco, CA, ...
The US Food and Drug Administration (FDA) has granted Priority Review for its New Drug Application (NDA) for zongertinib (BI 1810631), a treatment for adults with advanced non-small cell lung cancer (NSCLC) characterized by HER2 (ERBB2) mutations who have undergone prior ...
Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise ...
What’s new in GI oncology? With the 2025 ASCO Gastrointestinal Cancers Symposium still fresh in our minds, we hear from leading experts on the key abstracts and presentations from the conference in the fields of colorectal and pancreatic cancer. Circulating ...
Bruton tyrosine kinase (BTK) plays a functional and integral role in B-cell receptor (BCR) signalling and is expressed in normal and malignant B cells. Given BTK’s central role in the survival and proliferation of malignant B cells, BTK inhibitors ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
